Shanghai Institute of Material Medical Chinese Academy of Sciences

Biography

TAN Changheng received his PhD degree from Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences (CAS), in 2001, under the supervision of Prof. ZHU Dayuan. He is a full professor and principle investigator (PI) of SIMM, CAS, since 2009. His main research interests are the finding of novel structures and/or bioactive ingredients from traditional Chinese medicines (TCMs) or the other medicinal plants, the SAR of bioactive natural ingredients, and the quality control of TCMs or functional foods. He investigated systematically the phytochemicals of more than 100 TCMs, resulted into more 200 academic publications and 7 authorized China patents. Furthermore, 6 Ph.D and 21 master students had been trained under his guide.

EDUCATION

09/15/1989 - 07/06/1993, Nanchang University

08/24/1996 - 07/06/2001, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

WORK EXPERIENCE

07/07/1993 - 08/22/1996, Nanchang University

07/07/2001 - present, Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Research Directions

1. Novel structures and bioactive ingredients from medicinal plants;

2. The process study of active pharmaceutical ingredients from TCMs;

3. SAR and structural modification of bioactive natural compounds;

4. Bioactive natural products-based R & D of drug.

Grants & Research Projects

Enterprise. R & D of Chongming Kucao. 2019.11-2022.10

The National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, the National Health Commission (NHC), China. Rapid discovery and key technologies of active components of traditional Chinese medicine against organ tissue fibrosis. 2019.1 - 2020.12

The National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, NHC, China. The pre-clinical study of SAB-a anti-IPF drug candidate. 2019.1 - 2020.12

Strategic Priority Research Program, CAS, China. The discovery of lead compounds targeting dopamine D5 receptor in the treatment of attention deficit hyperactivity disorder (ADHD)". 2016.1-2017.12.

The National Science & Technology Major Project Key New Drug Creation and Manufacturing Program, the Ministry of Science and technology (MOST), China, The preclinical research of ZT – 1, a drug candidate for preventing nerve agents. 2008.1-2011.12

863 project, MOST, China, Studies on key technologies of artificial large-scale production of rare medicinal plants - Licorice and Huperzia serrata, 2007.10-2010.9.

The National Natural Science Foundation of China (NSFC), The SAR studies of Q1, a natural anti-HBV agent, 2011.1-2013.12

NFSC. Study on the active components of three medicinal plants, 2013.1-2015.12.

Achievements

PBSS1113—a antitumor drug candidate based on inhibiting USP28/25

DAD – an ADHD drug candidates based on agitating dopamine receptor DRD5.

QH197 – a natural product-based anti-hepatitis C drug candidate.

TC - 02 – a natural product-based nerve agent prevention drug candidate.

SAB-01 – an IPF (idiopathic pulmonary fibrosis) drug candidate based on active ingredient of Radix Salviae Miltiorrhizae.

HSYA-02 – a NASH drug candidate based on active ingredient of Flos Carthami.

JL - 06 – a CVD (cardiovascular disease) drug candidate based on active ingredient of Fructus Tribuli.

morefold

Social Titles

morefold

Awards & Honors

morefold

Pubilcations

Full Publication List

Selected Publications

1.Xiao-Feng Wang^, Zhengdan Zhu^, Ting-Ting Hao^, Qiang-Qiang Fang, Kun Jiang, Shi-Jin Qu, Jiang-Pin Zuo, Weiliang Zhu, Shi-Jun He*, Chang-Heng Tan* Alopecines A – E, five chloro-containing matrine-type alkaloids with immunosuppressive activities from the seeds of Sophora alopecuroides. Bioorganic Chemistry, 2020, 99, 103812.

2.Qi-Qi Wang^, Xiao-Dong Wang^, Ling-Zhi Wu, Qiang-Qiang Fang, Ya-Nan Liu, Kun Jiang, Shi-Jin Qu*, Chang-Heng Tan*. Polyprenylated acylphloroglucinols as deubiquitinating protease USP7 inhibitors from Hypericum hookerianum, Fitoterapia, 2020, 146, 104678.

3.Rui-Yuan Pan, Jun Ma, Xiang-Xi Kong, Xiao-Feng Wang, Shuo-Shuo Li, Xiao-Long Qi, Jin-Bo Cheng, Qing-Song Liu, Wan-Zhu Jin, Chang-Heng Tan, Zeng-Qiang Yuan*. Sodium rutin ameliorates Alzheimer’s disease-like pathology by enhancing microglial amyloid- clearance. Science Advances. 2019; 5, eaau6328.

4.Xiao-Feng Wang, Fei-Fei Liu, Zhengdan Zhu, Qiang-Qiang Fang, Shi-Jin Qu, Weiliang Zhu, Li Yang*, Jian-Ping Zuo, Chang-Heng Tan*, Flueggenoids A – E, new dinorditerpenoids from Flueggea virosa. Fitoterapia 2019, 133, 96-101.

5.Dou-Dou Dong^, Heng Li^, Kun Jiang, Shi-Jin Qu, Wei Tang, Chang-Heng Tan*, Yi-Ming Li*. Diverse lignans with anti-inflammatory activity from Urceola rosea. Fitoterapia 2019, 134, 96-100.

6.Ma Y-Q, Liu M-H, Tan T, Yan A-P, Guo L., Jiang K., Tan C-H*, Wan Y-Q*. Deep eutectic solvents used as extraction solvent for the determination of flavonoids from Camellia oleifera flowers by high-performance liquid chromatography. Phytochem. Anal. 2018, 29(6), 639-648.

7.Wang W.-P., Jiang K., Zhang P., Shen K.-K., Qu S.-J., Yu X.-P., Tan C.-H*. Highly oxygenated and structurally diverse diterpenoids from Euphorbia helioscopia. Phytochemistry, 2018, 145, 93–102.

8.Liu, Z.-L., Zhu, H.-R., Qu, S.-J., Tang, L.-S., Cao, L.-H., Yu, W.-B., Yang, X.-M., Jiang, S.-M., Zhu, D.-Y., Tan, C.-H.*, Yu, L.* Pyramidatine (Z88) sensitizes vincristine-resistant human oral cancer (KB/VCR) cells to chemotherapeutic agents by inhibition of P-glycoprotein. Anticancer Agents Med Chem, 2018, 18(2), 286-294.

9.Yi-Ming Zhai, Kun Jiang, Shi-Jin Qu, Hong-Feng Luo, Jun-Jie Tan, Chang-Heng Tan*. Structurally diverse stilbene dimers from Gnetum montanum Markgr: studies on the 1H chemical shift differences between dimeric stilbene epimers correlating to the relative configurations. RSC Adv., 2016, 6, 50083–50090.

10.Zhu, Da-Yuan; Tan, Chang-Heng; Li, Yi-Ming. (Ch.4)The overview of studies on huperzine A: a natural drug for the treatment of Alzheimer's disease. Eds.: Liang, Xiao-Tian, Fang, Wei-Shuo. Medicinal Chemistry of Bioactive Natural Products (2006):143-182.

morefold